Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other financing activities: 2018-2022

  • Editas Medicine's Other financing activities fell 30.23% to $367,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $1.5 million, marking a year-over-year increase of 0.33%. This contributed to the annual value of $979,000 for FY2022, which is 15.02% down from last year.
  • As of Q2 2022, Editas Medicine's Other financing activities stood at $367,000, which was down 30.23% from $526,000 recorded in Q2 2021.
  • In the past 5 years, Editas Medicine's Other financing activities registered a high of $526,000 during Q2 2021, and its lowest value of $283,000 during Q2 2019.
  • Moreover, its 3-year median value for Other financing activities was $367,000 (2022), whereas its average is $414,333.
  • As far as peak fluctuations go, Editas Medicine's Other financing activities skyrocketed by 50.29% in 2021, and later slumped by 30.23% in 2022.
  • Over the past 5 years, Editas Medicine's Other financing activities (Quarterly) stood at $362,000 in 2018, then declined by 21.82% to $283,000 in 2019, then rose by 23.67% to $350,000 in 2020, then spiked by 50.29% to $526,000 in 2021, then tumbled by 30.23% to $367,000 in 2022.
  • Its last three reported values are $367,000 in Q2 2022, $526,000 for Q2 2021, and $350,000 during Q2 2020.